---
schema_version: "secwatch.filing_event.v1"
accession: "0000010795-23-000026"
form_type: "8-K"
ticker: "BDX"
cik: "0000010795"
company_name: "BECTON DICKINSON & CO"
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T01:48:16.231188+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BD reports Q1 FY2023 revenue $4.6B (-2.8% as reported); adj. EPS $2.98; raises guidance

## Summary
- Revenue of $4,586M decreased 2.8% as reported, increased 1.7% currency-neutral versus Q1 FY2022.
- Base business (ex-COVID diagnostics) revenue grew 0.4% as reported, 5.2% currency-neutral.
- GAAP diluted EPS from continuing operations $1.70; adjusted diluted EPS $2.98, down 6.0% YoY.
- Company raises full-year fiscal 2023 revenue and adjusted EPS guidance.
- Results exclude spun-off Diabetes Care business (Embecta) accounted as discontinued operations.

## SEC filing metadata
- accession: 0000010795-23-000026
- form_type: 8-K
- ticker: BDX
- cik: 0000010795
- company_name: BECTON DICKINSON & CO
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10795/000001079523000026/0000010795-23-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10795/000001079523000026/bdx-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000010795-23-000026
- JSON: https://secwatch.observer/filing/0000010795-23-000026.json
- Plain text: https://secwatch.observer/filing/0000010795-23-000026.txt

## Key facts
- Earnings Releases
  BECTON DICKINSON & CO reported the first quarter of fiscal 2023 ended December 31, 2022 results: revenue $4.6 billion, EPS $1.70. Guidance raised.
  - Period: the first quarter of fiscal 2023 ended December 31, 2022
  - Revenue: $4.6 billion
  - EPS: $1.70
  - Guidance: raised
  - Result: reported results
  source text: BD Reports First Quarter Fiscal 2023 Financial Results Execution of BD 2025 Strategy Delivering Consistent and Durable Performance • Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis • Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral • GAAP and adjusted diluted EPS from continuing operations of $1.70 and $2.98, respectively • Company raises full-year revenue and adjusted EPS guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/10795/000001079523000026/0000010795-23-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.